Literature DB >> 11096547

Restrictive Cardiomyopathy.

.   

Abstract

Of the three major functional categories of cardiomyopathies (dilated, hypertrophic, and restrictive), the restrictive cardiomyopathies (RCMs) are the least common in the Western world, but unfortunately often are associated with the greatest morbidity and mortality. Infiltrative disease of the myocardium (often caused by amyloidosis) is a common cause of RCMs and has a significantly lower long-term survival rate when compared to cardiomyopathies of various other causes. Treatment of the RCM is, in general, difficult and often ineffective. Because of the abnormalities of diastolic filling that are characteristic of this condition, general measures to reduce venous and systemic congestion such as with the use of diuretics, are desirable but often result in an attendant reduction in stroke volume and cardiac output. Digoxin, calcium channel blocking drugs, and beta-adrenergic blocking agents are of limited value, although they may be used with benefit to control the heart rate response in the subgroup of patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors are generally ineffective in RCM. Targeted therapy directed against specific causal entities (such as the use of somatostatin analogues in carcinoid syndrome or iron chelation with desferrioxamine in hemochromatosis) may be more effective than simple symptomatic therapy. Differentiation of RCM from constrictive pericarditis is crucial, since constriction may be treated effectively by surgical removal of the thickened pericardium. A limited number of patients appear to have benefited from novel treatment strategies, such as autologous stem cell transplant in amyloidosis, balloon valvuloplasty of stenotic tricuspid or pulmonary valves in cardiac carcinoid syndrome, and cardiac transplantation. Truly effective therapy for RCM is generally lacking, and the best chance for optimizing the clinical outcome is early detection and aggressive medical treatment in an attempt to maintain the highest possible level of patient function for as long as possible.

Entities:  

Year:  2000        PMID: 11096547     DOI: 10.1007/s11936-000-0038-6

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  18 in total

1.  Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy.

Authors:  S V Rajkumar; M A Gertz; R A Kyle
Journal:  Am J Med       Date:  1998-03       Impact factor: 4.965

Review 2.  Eosinophilia.

Authors:  M E Rothenberg
Journal:  N Engl J Med       Date:  1998-05-28       Impact factor: 91.245

Review 3.  Restrictive cardiomyopathy.

Authors:  S S Kushwaha; J T Fallon; V Fuster
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

4.  Cardiac sarcoidosis.

Authors:  D N Mitchell; R M du Bois; P J Oldershaw
Journal:  BMJ       Date:  1997-02-01

5.  Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

Authors:  M Skinner; J Anderson; R Simms; R Falk; M Wang; C Libbey; L A Jones; A S Cohen
Journal:  Am J Med       Date:  1996-03       Impact factor: 4.965

6.  Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis.

Authors:  M van Buren; R J Hené; L F Verdonck; F J Verzijlbergen; H M Lokhorst
Journal:  Ann Intern Med       Date:  1995-04-01       Impact factor: 25.391

Review 7.  Restrictive cardiomyopathies.

Authors:  N Spyrou; R Foale
Journal:  Curr Opin Cardiol       Date:  1994-05       Impact factor: 2.161

8.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

Authors:  G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

9.  Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis.

Authors:  A Pollak; R H Falk
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

10.  Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival.

Authors:  S Dubrey; R W Simms; M Skinner; R H Falk
Journal:  Am J Cardiol       Date:  1995-10-01       Impact factor: 2.778

View more
  8 in total

1.  Effects of selective I f-channel inhibition with ivabradine on hemodynamics in a patient with restrictive cardiomyopathy.

Authors:  Philip Wenzel; Nico Abegunewardene; Thomas Münzel
Journal:  Clin Res Cardiol       Date:  2009-08-27       Impact factor: 5.460

Review 2.  Mesoscopic analysis of motion and conformation of cross-bridges.

Authors:  J Borejdo; R Rich; K Midde
Journal:  Biophys Rev       Date:  2012-04-17

3.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.

Authors:  J Malcom; O Arnold; Jonathan G Howlett; Anique Ducharme; Justin A Ezekowitz; Martin J Gardner; Nadia Giannetti; Haissam Haddad; George A Heckman; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2008-01       Impact factor: 5.223

4.  Functional effects of a restrictive-cardiomyopathy-linked cardiac troponin I mutation (R145W) in transgenic mice.

Authors:  Yuhui Wen; Yuanyuan Xu; Yingcai Wang; Jose Renato Pinto; James D Potter; W Glenn L Kerrick
Journal:  J Mol Biol       Date:  2009-08-03       Impact factor: 5.469

5.  Dose-dependent diastolic dysfunction and early death in a mouse model with cardiac troponin mutations.

Authors:  Yuejin Li; Lei Zhang; Pierre-Yves Jean-Charles; Changlong Nan; Guozhen Chen; Jie Tian; J-P Jin; Ira J Gelb; Xupei Huang
Journal:  J Mol Cell Cardiol       Date:  2013-06-26       Impact factor: 5.000

6.  Insights into restrictive cardiomyopathy from clinical and animal studies.

Authors:  Pierre-Yves Jean-Charles; Yue-Jin Li; Chang-Long Nan; Xu-Pei Huang
Journal:  J Geriatr Cardiol       Date:  2011-09       Impact factor: 3.327

7.  Troponin Mutation Caused Diastolic Dysfunction and Experimental Treatment in Transgenic Mice with Cardiomyopathy.

Authors:  Yang Xu; Jie Tian; Xupei Huang
Journal:  GSTF J Adv Med Res       Date:  2015-07-09

8.  Green tea extract catechin improves cardiac function in pediatric cardiomyopathy patients with diastolic dysfunction.

Authors:  Junjun Quan; Zhongli Jia; Tiewei Lv; Lei Zhang; Lingjuan Liu; Bo Pan; Jing Zhu; Ira J Gelb; Xupei Huang; Jie Tian
Journal:  J Biomed Sci       Date:  2019-05-08       Impact factor: 8.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.